All MO HealthNet Providers

Rate Increase

The Centers for Medicare & Medicaid Services has approved the MO HealthNet Division (MHD) state plan amendment for the July 1, 2022 provider rate increase. The claims processing system has been updated with the new maximum allowable reimbursement rates. MHD will reprocess claims paid for dates of service on or after July 1, 2022. However, MHD will not reprocess any claims billed with units that exceed the new daily maximum quantity. Providers will need to adjust any claims that require changes to quantity of units billed.

Launch of the MO HealthNet Division Show Me Healthy Kids (SMHK) Webpage

The MO HealthNet Division (MHD) launched a dedicated webpage for the Home State Health Show Me Healthy Kids (SMHK) managed care health plan. SMHK is a specialized health plan that provides integrated medical health, behavioral health, and care management services to children and youth in the care of the state, receiving adoption or guardianship subsidy assistance, or persons under age 26 formerly in foster care.

The Cuff Kit Project Information

The Missouri Hospital Association (MHA) and the Missouri Maternal-Child Learning and Action Network are pleased to announce funding from the Missouri Department of Health and Senior Services COVID-19 Statewide Health Disparities Initiative Grant to support The Cuff Kit™ Project through the Preeclampsia Foundation (PF). The Cuff Kit™ Project allows for distribution of blood pressure (BP) cuff kits to vulnerable maternal patients at high-risk for or diagnosed with blood pressure-related issues.

Reminder for Children's Division Residential and Treatment Foster Care Providers

Effective October 1, 2022, residential and treatment foster care (TFC) providers must begin submitting claims for the comprehensive community support (CCS) rehab per diem either to Show Me Healthy Kids (SMHK) plan, managed by Home State Health, or to MO HealthNet Division (MHD) fee-for-service, depending on the individual’s coverage.

RSV Prophylaxis

Respiratory syncytial virus (RSV) activity in the United States remains variable by region but is increasing in some parts of Missouri, including St. Louis and Kansas City metropolitan areas. The shift in seasonality for RSV was first noted in 2021. The American Academy of Pediatrics (AAP) supports the use of palivizumab in eligible infants in any region experiencing rates of RSV activity at any time in 2022, similar to a typical (pre-2020) fall-winter season.